Hjem › Brystkræft › Georgia

Brystkræft kliniske forsøg i Georgia

53 studier for Brystkræft søger deltagere på steder i Georgia.

Byer i Georgia

Officiel studietekst (engelsk)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Northeast Georgia Medical Center Braselton, Braselton
Atlanta VA Medical Center, Decatur
Northeast Georgia Medical Center-Gainesville, Gainesville
og 4 flere

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne

Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer

Winship Cancer Institute, Emory University, Atlanta

RekruttererFase 2

Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06369285

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy

Emory Proton Therapy Center, Atlanta

RekruttererFase 3

Alder 19 og opefter · Kvinder · Opdateret 29. sep. 2026 · NCT05856773

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Emory University Hospital, Atlanta

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05646862

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

City of Hope Cancer Center - Atlanta ( Site 0102), Newnan

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06966700

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032), Thomasville

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06312176

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Emory University Winship Cancer Institute, Atlanta
Liberty County Cancer Care, Hinesville
Pembroke Medical Oncology & St Joseph's/Candler Oncology Infusion Suite, Pembroke
og 2 flere

RekruttererFase 3

Alder 60 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06377852

Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer

Clinical Trial Site, Marietta

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 23. sep. 2026 · NCT07085767

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

Piedmont Columbus Regional - John B. Amos Cancer Center, Columbus
Central Georgia Cancer Care, Macon
City of Hope National Medical Center, Atlanta Cancer Center, Newnan
og 2 flere

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07174336

A Study of LY4257496 in Participants With Cancer (OMNIRAY)

Emory University School of Medicine - Winship Cancer Institute, Atlanta

RekruttererFase 1

Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07114601

A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer

Winship Cancer Institute, Atlanta

RekruttererFase 2

Alder 18 og opefter · Kvinder · Opdateret 22. sep. 2026 · NCT07287098

A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer

University Cancer & Blood Center, LLC, Athens
Winship Cancer Institute of Emory University, Atlanta

RekruttererFase 1/2

Alder 18 og opefter · Alle køn · Opdateret 17. sep. 2026 · NCT06827236

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence

University Blood & Cancer Center, LLC, Athens
Winship Cancer Institute, Atlanta
Northside Hospital, Atlanta

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 15. sep. 2026 · NCT06492616

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Georgia Cancer Center at Augusta University, Augusta

RekruttererFase 1

Alder 18 og opefter · Alle køn · Opdateret 10. sep. 2026 · NCT06293898

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

Emory University (Data Collection Only), Atlanta

RekruttererFase 2

Alder 18 og opefter · Alle køn · Opdateret 9. sep. 2026 · NCT05570253

A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer

University Cancer & Blood Center, LLC, Athens
Summit Cancer Care, Savannah

RekruttererFase 1

Alder 18 til 55 · Kvinder · Opdateret 9. sep. 2026 · NCT07310420

A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer

Research Site, Marietta

RekruttererFase 3

Alder 18 til 130 · Alle køn · Opdateret 8. sep. 2026 · NCT07647328

A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer

Winship Cancer Institute of Emory University, Atlanta

RekruttererFase 1/2

Alder 18 og opefter · Alle køn · Opdateret 8. sep. 2026 · NCT07100106

A Study of Sofe-M in Participants With Selected Advanced Solid Tumors

Emory University, Atlanta

RekruttererFase 1

Alder 18 og opefter · Alle køn · Opdateret 4. sep. 2026 · NCT06400472

Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

Atlanta Cancer Care - Northside Hospital, Atlanta

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06982521

Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers

Emory University, Atlanta

RekruttererFase 2

Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT05846789

A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer

Northwest Georgia Oncology Centers PC - Marietta, Marietta

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT06790693

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Phoebe Putney Memorial Hospital, Albany
University Cancer and Blood Center LLC, Athens
Grady Health System, Atlanta
og 16 flere

RekruttererFase 3

Alder 18 til 60 · Kvinder · Opdateret 2. sep. 2026 · NCT05879926

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Winship Cancer Institute of Emory University, Atlanta

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 2. sep. 2026 · NCT06072612

Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma

Emory University - Winship Cancer Institute, Atlanta

RekruttererFase 1

Alder 18 og opefter · Alle køn · Opdateret 27. aug. 2026 · NCT06582017

A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases

Augusta University, Augusta

RekruttererFase 2

Alder 18 og opefter · Alle køn · Opdateret 21. aug. 2026 · NCT06764940

Mobile Health Patient Navigation for the Improvement of Screening and the Early Detection of Breast Cancer in Women Accessing Primary Care Clinics in Kenya

Emory University Hospital/Winship Cancer Institute, Atlanta

RekruttererFrivillige med god helbredstilstand velkomne

Alder 18 og opefter · Alle køn · Opdateret 14. aug. 2026 · NCT07764796

Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC

Winship Cancer Institute at Emory University, Atlanta

RekruttererFase 2

Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT06263543

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

Emory University, Atlanta

RekruttererFase 1

Alder 18 og opefter · Alle køn · Opdateret 12. aug. 2026 · NCT05304962

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Northside Hospital, Atlanta

RekruttererFase 2/3

Alder 18 og opefter · Alle køn · Opdateret 10. aug. 2026 · NCT06926868

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects

City of Hope - Cancer Center Atlanta, Newnan

RekruttererFase 3

Alder 18 til 100 · Alle køn · Opdateret 6. aug. 2026 · NCT05232916

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Augusta University Georgia Cancer Center, Augusta

RekruttererFase 1/2

Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT05579366

E-Mindfulness Approaches for Living After Breast Cancer

Grady Health System, Atlanta
Emory University Hospital Midtown, Atlanta
Emory University Hospital/Winship Cancer Institute, Atlanta
og 3 flere

RekruttererFase 3

Alder 18 til 50 · Alle køn · Opdateret 4. aug. 2026 · NCT06748222

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Emory University, Atlanta

RekruttererFase 1/2

Alder 18 og opefter · Alle køn · Opdateret 30. jul. 2026 · NCT07288359

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

RekruttererFase 1/2

Alder 18 og opefter · Alle køn · Opdateret 7. jul. 2026 · NCT05768139

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

Winship Cancer Institute, Emory University, Atlanta

RekruttererFase 1/2

Alder 18 og opefter · Alle køn · Opdateret 29. jun. 2026 · NCT05377996

A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study

GSK Investigational Site, Atlanta

RekruttererFase 2

Alder 18 og opefter · Alle køn · Opdateret 24. jun. 2026 · NCT04641247

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Emory University School of Medicine, Atlanta

RekruttererFase 3

Alder 18 og opefter · Alle køn · Opdateret 22. jun. 2026 · NCT05696626

Evaluating an Evidence-Based Family History Screening Program Adapted to Increase Reach and Uptake of Screening for BRCA-Associated Cancers in Rural Public Health Clinics

Emory University Hospital/Winship Cancer Institute, Atlanta

RekruttererFrivillige med god helbredstilstand velkomne

Alder 25 og opefter · Kvinder · Opdateret 26. maj 2026 · NCT06760507

Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab

Emory University/Winship Cancer Institute, Atlanta

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne

Alder 18 og opefter · Kvinder · Opdateret 7. maj 2026 · NCT05877859

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.